RedHill Biopharma Collaborates with NIAID to Investigate RHB-107 (upamostat, WX-671) Against COVID-19
RedHill Biopharma’s Talicia Received the US FDA’s Approval for H. pylori in Adults
Shots:
- RedHill in collaboration with NIAID will evaluate RHB-107 in non-clinical studies to determine its activity against SARS-CoV-2. The agreement will facilitate the pre-clinical evaluation of RHB-107 as a treatment for COVID-19
- Additionally, RedHill is evaluating opaganib (Yeliva, ABC294640) against COVID-19. On Apr 17, the company unveils about the compassionate use of Opaganib is underway in Israel, with several patients treated to date and preliminary positive outcomes
- RHB-107 is a serine protease inhibitor active against trypsins and other related serine proteases, being evaluated in 300+ people across 10 clinical studies, including two completed P-II studies in oncology patients and multiple P-I studies in healthy volunteers and oncology patients
Click here to read full press release/ article | Ref: RedHill | Image: Twitter